Clinical trial
Efficacy and Safety of Tegaserod in Opioid-induced Constipation in Patients With…
NCT00365820 · Novartis, Industry · Terminated
Key facts
| NCT number | NCT00365820 |
|---|---|
| Title | Efficacy and Safety of Tegaserod in Opioid-induced Constipation in Patients With Non-cancer Pain |
| Official title | A Randomized, Double-blind, Placebo-controlled Multicenter Phase II/III Study to Evaluate the Efficacy and Safety of Tegaserod and Placebo Given Orally for 12 Weeks for the Treatment of Opioid-induced Constipation (OIC) in Patients With Chronic Non-cancer Pain |
| Lead sponsor | Novartis, Industry |
| Status | Terminated |
| Phase | Phase 2/Phase 3 |
| Study type | Interventional |
| Conditions | Constipation |
| Intervention type | Drug |
| Interventions | Tegaserod |
| Enrollment | 670 |
| Start date | Jul 1, 2006 |
| Primary completion | Apr 1, 2007 |
| Completion | Apr 1, 2007 |
| First posted | Aug 18, 2006 |
| Last update posted | Apr 20, 2012 |
| Countries | United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: